Literature DB >> 28861329

MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1.

Xiaoming Yang1, Lei Shi1, Chengzhi Yi1, Yang Yang1, Liansheng Chang1, Dongkui Song1.   

Abstract

Current evidence indicates that microRNAs are widely down-regulated in various tumors including colorectal carcinoma, liver cancer and lung cancer, and function as tumor suppressors through inhibiting cancer cell growth, invasion and migration. Here, we demonstrated that miR-210-3p level was significantly reduced in the bladder cancer compared to paratumor tissues, and attempt to reveal the regulatory role of miR-210-3p in bladder cancer progression. Exogenous overexpression of miR-210-3p inhibited the proliferation, migration and invasion of bladder cancer cells in vitro. In addition, the nude mouse xenograft model showed that miR-210-3p over-expressing inhibited bladder cancer growth and liver metastasis whereas silencing miR-210-3p caused an opposite outcome, which is mainly regulated by targeting fibroblast growth factor receptor-like 1 (FGFRL1). We also demonstrated that the expression of FGFRL1 in bladder cancer specimens were negatively correlated with miR-210-3p level, and FGFRL1 overexpression rescued the cell proliferation and invasion inhibited by ectopic expression of miR-210-3p. Moreover, knockdown of FGFRL1 was able to mimic the cell growth and metastasis effects induced by miR-210-3p over-expressing in bladder cancer cells. Together, these results indicate that miR-210-3p plays an important role in the regulation of bladder cancer growth and metastasis in vitro and in vivo through targeting FGFRL1.

Entities:  

Keywords:  Bladder cancer; FGFRL1; metastasis; miR-210-3p

Year:  2017        PMID: 28861329      PMCID: PMC5574945     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  21 in total

1.  MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1).

Authors:  Soken Tsuchiya; Takeshi Fujiwara; Fumiaki Sato; Yutaka Shimada; Eiji Tanaka; Yoshiharu Sakai; Kazuharu Shimizu; Gozoh Tsujimoto
Journal:  J Biol Chem       Date:  2010-11-02       Impact factor: 5.157

2.  Aberrant expression of FGFRL1, a novel FGF receptor, in ovarian tumors.

Authors:  Christof Schild; Beat Trueb
Journal:  Int J Mol Med       Date:  2005-12       Impact factor: 4.101

3.  MicroRNA-205 functions as a tumor suppressor in colorectal cancer by targeting cAMP responsive element binding protein 1 (CREB1).

Authors:  Peng Li; Wan-Jiang Xue; Ying Feng; Qin-Sheng Mao
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

4.  miR-210 is a prognostic marker in clear cell renal cell carcinoma.

Authors:  Sara Samaan; Heba W Z Khella; Andrew Girgis; Andreas Scorilas; Evi Lianidou; Manal Gabril; Sergey N Krylov; Michael Jewett; Georg A Bjarnason; Hala El-said; George M Yousef
Journal:  J Mol Diagn       Date:  2014-12-31       Impact factor: 5.568

5.  Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.

Authors:  Mark C Korpics; Alec M Block; Brendan Martin; Courtney Hentz; Ellen R Gaynor; Elizabeth Henry; Matthew M Harkenrider; Abhishek A Solanki
Journal:  Cancer       Date:  2017-06-05       Impact factor: 6.860

6.  miR-449a promotes liver cancer cell apoptosis by downregulation of Calpain 6 and POU2F1.

Authors:  Yonglei Liu; Yutong Wang; Xiangjun Sun; Chuanzhong Mei; Liying Wang; Zengxia Li; Xiliang Zha
Journal:  Oncotarget       Date:  2016-03-22

Review 7.  Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer.

Authors:  Mahdi Afshari; Ghasem Janbabaei; Mohammad Amin Bahrami; Mahmood Moosazadeh
Journal:  PLoS One       Date:  2017-06-06       Impact factor: 3.240

8.  microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma.

Authors:  Hirofumi Yoshino; Masaya Yonemori; Kazutaka Miyamoto; Syuichi Tatarano; Satoshi Kofuji; Nijiro Nohata; Masayuki Nakagawa; Hideki Enokida
Journal:  Oncotarget       Date:  2017-03-28

9.  Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma.

Authors:  Alan Ka-Lun Kai; Lo Kong Chan; Regina Cheuk-Lam Lo; Joyce Man-Fong Lee; Carmen Chak-Lui Wong; Jack Chun-Ming Wong; Irene Oi-Lin Ng
Journal:  Hepatology       Date:  2016-04-30       Impact factor: 17.425

10.  POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer.

Authors:  Daniel J Sharpe; Katy S Orr; Michael Moran; Sharon J White; Stephen McQuaid; Terence R Lappin; Alexander Thompson; Jacqueline A James
Journal:  Oncotarget       Date:  2014-09-30
View more
  15 in total

1.  MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K/AKT pathway.

Authors:  Shuo Liu; Qin Chen; Yue Wang
Journal:  Hum Cell       Date:  2019-10-11       Impact factor: 4.174

2.  MiR-192-5p suppresses the growth of bladder cancer cells via targeting Yin Yang 1.

Authors:  Decai Ji; Lining Jiang; Yingjie Li
Journal:  Hum Cell       Date:  2018-03-13       Impact factor: 4.174

Review 3.  Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.

Authors:  Ulrich H Weidle; Fabian Birzele
Journal:  Cancer Diagn Progn       Date:  2021-07-03

4.  Comparative Profiling of Circulating Exosomal Small RNAs Derived From Peruvian Patients With Tuberculosis and Pulmonary Adenocarcinoma.

Authors:  Heinner Guio; Victor Aliaga-Tobar; Marco Galarza; Oscar Pellon-Cardenas; Silvia Capristano; Henry L Gomez; Mivael Olivera; Cesar Sanchez; Vinicius Maracaja-Coutinho
Journal:  Front Cell Infect Microbiol       Date:  2022-06-30       Impact factor: 6.073

5.  miR-210-3p Promotes Lung Cancer Development and Progression by Modulating USF1 and PCGF3.

Authors:  Qian Chen; Hongyu Zhang; Jianyin Zhang; Le Shen; Jing Yang; Yan Wang; JinXiu Ma; Bing Zhuan
Journal:  Onco Targets Ther       Date:  2021-06-09       Impact factor: 4.147

6.  An integrated analysis of key microRNAs, regulatory pathways and clinical relevance in bladder cancer.

Authors:  Dongyang Li; Xuanyu Hao; Yongsheng Song
Journal:  Onco Targets Ther       Date:  2018-05-24       Impact factor: 4.147

7.  Lung CSC-derived exosomal miR-210-3p contributes to a pro-metastatic phenotype in lung cancer by targeting FGFRL1.

Authors:  Li Wang; Jun He; Haoyue Hu; Li Tu; Zhen Sun; Yanyang Liu; Feng Luo
Journal:  J Cell Mol Med       Date:  2020-05-12       Impact factor: 5.310

8.  miR-210 promotes human osteosarcoma cell migration and invasion by targeting FGFRL1.

Authors:  Xiangjun Liu; Chengfeng Zhang; Cunhua Wang; Jianwei Sun; Deliang Wang; Yansheng Zhao; Xiaohui Xu
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 2.967

9.  MiR-210-3p-EphrinA3-PI3K/AKT axis regulates the progression of oral cancer.

Authors:  Lin Wang; Yong Song; Hui Wang; Ke Liu; Zhe Shao; Zhengjun Shang
Journal:  J Cell Mol Med       Date:  2020-03-17       Impact factor: 5.310

10.  FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.

Authors:  Rui Chen; Deyu Li; Meng Zheng; Bin Chen; Ting Wei; Yu Wang; Man Li; Weimei Huang; Qin Tong; Qi Wang; Yaru Zhu; Wei Fang; Linlang Guo; Shun Fang
Journal:  J Cell Mol Med       Date:  2020-01-19       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.